Neurology Focused Pasithea Therapeutics Stock Soars Over 150% Today - Here's Why
Neurology Focused Pasithea Therapeutics Stock Soars Over 150% Today - Here's Why
Pasithea Therapeutics Corp (NASDAQ:KTTA) announced preclinical results from two in vivo studies evaluating the antitumor efficacy of PAS-004 in NRAS mutation cancer xenograft models.
Pasithea Therapeutics Corp（納斯達克股票代碼：KTTA）公佈了兩家公司的臨床前結果 在活體中 評估 PAS-004 在 NRAS 突變癌異種移植模型中的抗腫瘤功效的研究。
In the first study, PAS-004 exhibited dose-dependent antitumor efficacy in the lung cancer NCI-H1299 cell-line-derived xenograft model. PAS-004 at dose levels of 10 mg/kg and 5 mg/kg, once daily, significantly inhibited tumor growth compared to vehicle control.
在第一項研究中，PAS-004 在肺癌 NCI-H1299 細胞系衍生異種移植模型中表現出劑量依賴性的抗腫瘤功效。與車輛控制相比，劑量水平爲 10 mg/kg 和 5 mg/kg 的 PAS-004 每天一次，可顯著抑制腫瘤的生長。
The antitumor efficacy of PAS-004, when taken at equivalent doses, was shown to be superior to that of Pfizer Inc's (NYSE:PFE) Mektovi (binimetinib) and AstraZeneca Plc's (NASDAQ:AZN) Koselugo (selumetinib).
事實證明，以等效劑量服用 PAS-004 的抗腫瘤療效優於輝瑞公司（紐約證券交易所代碼：PFE）的Mektovi（binimetinib）和阿斯利康公司（納斯達克股票代碼：AZN）的Koselugo（塞盧美替尼）。
In the second study, PAS-004 exhibited dose-dependent antitumor efficacy in the liver cancer xHepG2 cell-line-derived xenograft model. PAS-004 at dose levels of 10 mg/kg and 5 mg/kg, once daily, produced significant antitumor activities compared to vehicle control.
在第二項研究中，PAS-004 在肝癌 xHepG2 細胞系衍生異種移植模型中表現出劑量依賴性的抗腫瘤功效。與車輛控制相比，劑量水平爲 10 mg/kg 和 5 mg/kg 的 PAS-004 每天一次，可產生顯著的抗腫瘤活性。
The antitumor efficacy of PAS-004, when taken at equivalent doses, was shown to be similar to that of binimetinib and superior to that of selumetinib.
事實證明，當以等劑量服用時，PAS-004 的抗腫瘤功效與比尼美替尼相似，優於塞魯美替尼。
The company plans to start the Phase 1 study as early as the first quarter of 2024, following acceptance of the company's Investigational New Drug Application (IND) with the FDA.
該公司計劃最早在2024年第一季度開始1期研究，此前該公司的研究性新藥申請（IND）已被FDA接受。
Price Action: KTTA shares are up 172.90% at $0.82 during the premarket session on the last check Monday.
價格走勢：在週一最後一次支票的盤前交易中，KTTA股價上漲172.90％，至0.82美元。
譯文內容由第三人軟體翻譯。